Research Paper Volume 11, Issue 7 pp 2138—2150

MiR-204 reduces cisplatin resistance in non-small cell lung cancer through suppression of the caveolin-1/AKT/Bad pathway

Figure 5. miR-204/CAV-1 axis regulates the AKT/Bad pathway in cisplatin-resistant NSCLC cells. (A) Effect of miR-204 (50 pmol/ml), cisplatin (8 μM), and the CVA-1 plasmid (2 μg/ml) on the phosphorylation of AKT and Bad in CR-A549 and CR-PC9 cells. (B) A co-immunoprecipitation assay was performed to evaluate interactions with Bad and Bcl-xl/Bcl-2 after treatment with miR-204 (50 pmol/ml), cisplatin (8 μM), and the CVA-1 plasmid (2 μg/ml). (C) Effect of miR-204 (50 pmol/ml), cisplatin (8 μM), and the CVA-1 plasmid (2 μg/ml) on the mitochondrial membrane potential (ΔΨm) of CR-A549 and CR-PC9 cells.